ClinicalTrials.gg
TerminatedNCT03444311Updated Jul 8, 2020

Combined Nutritional Therapies for the Treatment of Ulcerative Colitis

An interventional study of A: 1 dosis and B: 2 dosis in Colitis, Ulcerative, sponsored by AB Biotics, SA. Terminated at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-08.

Sponsored by AB Biotics, SA (part of Kaneka Corporation) · Not applicable, Interventional, and Treatment

Why this study was terminated
Low tolerability of fibers included in the product

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 156 studies in Colitis, Ulcerative with a site in Spain — 20 open to participants now, 49 under way, 27 of them phase 3. Colitis, Ulcerative · Spain.

Enrollment
136th of 137
12 · median 217
Started
2018
with 18 others
No phase
14 of 156
2 open now
Registered
61st of 156
by date

Among the 156 studies in Colitis, Ulcerative with a site in Spain, this one is the 136th largest by enrollment of the 137 interventional ones that give a count, is one of 19 that started in 2018, is one of 14 with no phase, and was the 61st registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

20 of the 156 studies in Colitis, Ulcerative with a site in Spain are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Colitis, Ulcerative with a site in Spain, or all of them as a file.
02

Study summary

Ulcerative colitis (UC) is an entity of complex etiology where environmental, genetic and intestinal microflora-related factors trigger and perpetuate a chronic inflammation of the gastrointestinal tract. It is suspected that an alteration in primary intestinal microbial colonization (dysbiosis) could trigger, or at least contribute to, said oversized immune response. The hypothesis is that the administration of a series of fibers, could improve the bacterial diversity and repair the dysbiosis that has been seen in patients affected by ulcerative colitis, improving the clinical evolution of it. The primary objective of the present study is to know the impact on the microbiota of patients with UC in remission derived from the administration of dietary fibers. The RETOS study is a pilot project in which a population of patients with UC is tested for the effect on the composition of the microbiota that would have the administration of various combinations of fibers, in addition to the tolerability and acceptance by the patient. The clinical applicability derived from this intervention would be to improve the diversity of intestinal flora of patients with ulcerative colitis.

Read the detailed description

The Phase 1 study is a pilot project in which a population of patients with UC is tested for the effect on the composition of the microbiota that would have the administration of various combinations of fibers, in addition to the tolerability and acceptance by the patient. The study will include two groups of 20 patients each. One of the groups will receive 6 grams of fiber a day in a single shot with the main meal (group 1) and the other group will receive 12 grams of fiber a day divided into two meals with the main meals (group 2). Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.

Description of the administration pattern Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B

A second sequential cycle similar to the first one (4 weeks with the same administration pattern) will be repeated in order to confirm the reproducibility of the findings.

The two formulas contain fibers known and commonly used in human nutrition, which were previously tested in in vitro models with human faeces and their ability to promote the growth of butyrate-producing bacterial species that are deficient in patients with colitis was proven ulcerative (Faecalibacterium prausnitzii and Roseburia hominis). The fibers are presented in aluminum envelopes to dissolve in a glass of water, juice, infusion or cold cream (max 37 ° C).

In addition, formulas A and B for group 1 (a single intake per day) include the mixture of probiotics i3.1 in quantity per envelope of 3e + 9 colony-forming units, which contains: Pediococcus acidilactici CECT 7483, Lactobacillus plantarum CECT 7484 and Lactobacillus plantarum CECT 7485 in a 1: 1: 1 ratio. Formulas A and B for group 2 (two intakes per day) include the probiotic i3.1 in quantity per envelope of 1.5e + 09 colony-forming units.

In the two groups, the first week the patients will receive half of the dose with the aim of facilitating the adaptation in those people who usually do not consume fiber. The usual diet, tolerability and patient satisfaction will be controlled through biweekly predefined questionnaires.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • microbiota
  • ulcerative colitis
  • fiber
  • probiotic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (from 18 to 65 years old) diagnosed with ulcerative colitis (not distal), of at least 1 year of evolution of the disease.
  2. Patient in clinical remission two months prior to inclusion (Simple Colitis Clinical Activity Index (SCCAI) \<4) and fecal calprotectin \<150 μg / g.
  3. At least one outbreak in the last year that required systemic or escalating treatment (initiation of thiopurines, optimization of thiopurines, initiation of anti-TNF-alpha, intensification of anti-TNF-alpha, initiation of vedolizumab). At the time of entry into the study, the patient must carry with stable medication at least 2 months in the case of anti-TNF-alpha and mesalazine and 5 months in the case of thiopurine, and without treatment with corticosteroids

Exclusion criteria

Exclusion Criteria:

  • Patients with ulcerative proctitis only
  • Patients who have received antibiotics the month prior to inclusion until completion
  • Usual consumption of probiotics excluding fermented milk (yogurt, kefir ...).
  • Supplementation with dietary fiber (without taking into account the one administered in the study).
  • The smoking habit is allowed, although the beginning or abandonment of it from two months before the end of the study will have to be documented.
  • Patients undergoing hypocaloric diets
  • Patients with stenosis or intestinal surgery
  • Patients with primary sclerosing cholangitis
  • Patients under treatment with ursodeoxycholic acid
  • Patients under treatment with ion exchange resins
  • Patients under treatment with acenocoumarol (Sintrom)
  • The taking of proton pump inhibitors (PPIs) is allowed but their consumption must be controlled, not allowing them to start or suspend their intake during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    A: 1 dosis

    1 dosis (3E+09 cfu/day + 6 g of fiber/day)

    Dietary Supplement: A: 1 dosis

  • Active comparator
    B: 2 dosis

    2 dosis (3E+09 cfu/day + 12 g of fiber/day)

    Dietary Supplement: B: 2 dosis

Interventions

  • Dietary supplementA: 1 dosis

    1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups. Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B Composition of an envelope of formula A: Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6 Composition of an envelope of formula B: Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6

  • Dietary supplementB: 2 dosis

    1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups. Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B Composition of an envelope of formula A: Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6 Composition of an envelope of formula B: Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6

06

What researchers measure

Primary outcomes

  1. To know the impact on the microbiota diversity by 16S rRNA analysis of patients with UC in remission derived from the administration of a new product based on dietary fibers

    The phyla and genera relative abundance analysed by 16S rRNA before and after treatment with the two levels of fiber

    Time frame: 12 weeks

Secondary outcomes

  1. To study the tolerability of the product through questionnaires

    Change from baseline in tolerability scores using the DHRS scale (0 no pain-5 severe pain) every 15 days

    Time frame: 4 months

  2. To study the satisfaction of the product through questionnaires

    Change from baseline in satisfaction scores using a (0 do not like-10 like a lot)scale every 15 days

    Time frame: 4 months

07

Study locations

1 site
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jul 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Feb 23, 2018
StartActual
Mar 8, 2018
Primary completionActual
Jul 2, 2019
CompletionActual
Jul 2, 2020
Last update
Jul 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03444311
Lead sponsor
AB Biotics, SA
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Mar 8, 2018
Primary completion
Jul 2, 2019
Completion
Jul 2, 2020
Last update
Jul 8, 2020

Study contacts

Ariana Salavert, PhD
study director · Ab-biotics

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion